{
  "completed": true,
  "status": "completed_original_source_reconciliation",
  "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings",
  "queries": [
    "https://consensus.app/search/microdosing-lsd-for-depression/BU9_DPzcTSaBUkpuWcj5BQ/"
  ],
  "query_record_note": "Exact provider question/response retained privately in its retrieval receipt.",
  "primary_comparison_count": 9,
  "primary_comparisons": [
    {
      "pmid": "41202873",
      "doi": "10.1016/j.neuropharm.2025.110762",
      "source_type": "primary study report",
      "study_group": "PMID41202873",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Clinical positive versus newly discovered masked clinical conference null",
      "result_comparison": "Consensus accurately retains the19-person open-label MDD result and identifies a masked caffeine-comparator result. The latter was independently verified in the original September2026 Donegan conference abstract, DOI10.1093/ijnp/pyag040.021, rather than accepted from synthesis. It reports primary MADRS nonsuperiority and active-arm masking; it is not a complete trial publication or definitive equivalence. The open-label positive remains exploratory, while the separately receipted clinical null narrows its causal attribution.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/41202873/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\examinations\\original-20-30-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "35106880",
      "doi": "10.1111/adb.13143",
      "source_type": "primary study report",
      "study_group": "PMID35106880",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Dose units and actual placebo/guess assessment",
      "result_comparison": "Consensus labels13/26micrograms as low doses. Original text explicitly states these are LSD tartrate equivalent to10/20micrograms base, fitting the registered base range. Original Methods use water placebo and a possible-drug-category cover story with end-session guesses; actual Results show no residual mood improvement. A26-number label alone cannot justify excluding this study, and a design label cannot guarantee successful masking.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/35106880/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\examinations\\original-30-40-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\body-presentation-receipts\\35106880-pmc-selected-reviewer-notes.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\body-presentation-receipts\\35106880-s1-p0-1-3-4-5-6-8-9.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\body-presentation-receipts\\35106880-s2-p1-2-4-7-14-16-17.json"
      ]
    },
    {
      "pmid": "36997080",
      "doi": "10.1016/j.biopsych.2023.03.013",
      "source_type": "primary study report",
      "study_group": "ACTRN12621000436875",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Transient dose-day positives versus persistent symptom trajectory",
      "result_comparison": "Consensus accurately distinguishes dose-day mood elevations from no baseline-to-six-week questionnaire/cognitive change in80healthy men. Four anxiety withdrawals are important. Baseline-expectancy-adjusted acute effects do not automatically control postdose recognition or establish diagnosed-MDD treatment. The same-trial sleep and PK reports are grouped rather than counted as independent clinical replication.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/36997080/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\examinations\\original-10-20-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "33648632",
      "doi": "10.7554/eLife.62878",
      "source_type": "primary study report",
      "study_group": "PMID33648632",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Actual self-blinding methods and interpretation of guess adjustment",
      "result_comparison": "Consensus describes the self-blinding result as decisive on expectancy. Original Methods confirm participant-sourced uncontrolled substances/doses, randomized capsule schedules and forced guesses; Results show no accumulated benefit and loss of most acute/post-acute contrasts after guess adjustment. Recognition is a posttreatment variable and may carry genuine pharmacologic information, so this supports an expectancy alternative without proving all benefit is placebo.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/33648632/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\examinations\\original-0-10-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\body-presentation-receipts\\33648632-s1-p0-4-7-12-14-16-19-21-23.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\body-presentation-receipts\\33648632-s2-p0-3-6-8-14-17-18.json"
      ]
    },
    {
      "pmid": "33479342",
      "doi": "10.1038/s41598-021-81446-7",
      "source_type": "primary study report",
      "study_group": "PMID33479342",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Baseline expectancy as predictor rather than manipulated cause",
      "result_comparison": "Consensus correctly reports baseline expectations predicting wellbeing gains in the prospective81-completer observational cohort. The exposure and expectancy were not randomized. The result informs competing models but neither proves exclusive placebo causation nor identifies an independent drug effect.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/33479342/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\examinations\\original-30-40-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "34915762",
      "doi": "10.1177/02698811211050556",
      "source_type": "primary study report",
      "study_group": "PMID34915762",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Psilocybin symptom null and actual duration",
      "result_comparison": "Consensus correctly reports a controlled psilocybin microdose symptom null and second-block blind breaking. The original duration is three weeks and drug differs fromLSD; this is an observed companion boundary, not a complete direct4–12weekLSD-MDD refutation. Baseline decreases in one block do not become between-arm efficacy.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/34915762/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\examinations\\original-10-20-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "41187880",
      "doi": "10.1016/j.neuropharm.2025.110732",
      "source_type": "primary study report",
      "study_group": "PMID41187880",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Later restricted positive prevents blanket zero-effect claims",
      "result_comparison": "Consensus emphasizes many microdosing nulls but its source coverage does not exhaust the selected2026 originals. The original pooled171-person truffle creativity report finds a restricted originality-quality positive surviving dose-guess adjustment. It is retained alongside effectively blinded cognitive/emotional null41110634; creativity is not sustained depression treatment and likely shared trials restrict independence.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/41187880/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\examinations\\original-10-20-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "40105807",
      "doi": "10.1001/jamapsychiatry.2025.0044",
      "source_type": "primary study report",
      "study_group": "NCT05200936",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Repeated clinical dosing, masking and diagnosis boundary",
      "result_comparison": "The original ADHD trial adds clinically diagnosed six-week controlled evidence beyond the provider’s main healthy/MDD narrative. Actual Methods specify20micrograms base, on-site dosing and guesses; Results show no primary clinical superiority, with21/22active and16/24placebo guessing active after the last dose. Its secondary cognition report42322409 shares allocation. This marks an ADHD boundary without being relabeled anMDD result.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/40105807/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\examinations\\original-20-30-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\body-presentation-receipts\\40105807-s1-p0-1-2-3-7-8-12.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\body-presentation-receipts\\40105807-s2-p4-10-11-12-14.json"
      ]
    },
    {
      "pmid": "36322843",
      "doi": "10.1056/NEJMoa2206443",
      "source_type": "primary study report",
      "study_group": "NCT03775200",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Full-dose clinical results cannot become microdose proof",
      "result_comparison": "Consensus appropriately separates full-dose and ketamine treatment. Actual COMP360 primary25mg contrast is positive at three weeks but sustained week-twelve response is not supportive; full-dose33852780 and41848690 have primary nulls despite secondary positives. These exact outcomes are more informative than a broad class efficacy claim and cannot establish low-doseLSD generalization.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/36322843/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\examinations\\original-60-61-10000.json"
      ],
      "body_receipts": []
    }
  ],
  "grade_changed": false,
  "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.",
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\psychedelic-microdosing-symptoms\\consensus-browser-2026-10-13.json",
      "sha256": "269c514933087825c7e19f6ac368051b86eada2d18180dddb3015dadfb9bc16d"
    }
  ],
  "independent_blinded_audit": false,
  "cutoff": "2026-10-13",
  "completed_utc": "2026-10-13T17:35:23.417972+00:00",
  "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them."
}